首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display
【24h】

In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display

机译:使用cDNA显示体外选择生长激素促分泌素受体的肽拮抗剂

获取原文
获取原文并翻译 | 示例
       

摘要

G protein-coupled receptors (GPCRs) are major drug targets, and their ligands are currently being explored and developed by many pharmaceutical companies and independent researchers. Class A (rhodopsin-like) GPCRs compose a predominant GPCR family; there' fore, class A GPCR ligands are in demand. Growth hormone secretagogue receptor (GHS-R) is a class A GPCR that stimulates food intake by binding to its peptide ligand, ghrelin. Therefore, antago nists of GHS-R are expected to exert antiobesity function. In this article, we describe the use of cDNA display to screen for successfully and identify an antagonistic peptide of GHS-R. The antagonistic peptide inhibited the ghrelin-induced increase in intracellulai Ca~2+ in vitro (IC_(50)= approximately 10μM) and repressed the contraction of isolated animal stomach in response to ghrelin. Further more, peripheral administration of the peptide inhibited the fooc intake of mice. This work provides new insight into the development of antiobesity drugs and describes a method for the discovery of unique peptide ligands for class A GPCRs.
机译:G蛋白偶联受体(GPCR)是主要的药物靶标,许多制药公司和独立研究人员目前正在探索和开发其配体。 A类(视紫红质样)GPCR构成一个主要的GPCR家族。因此,需要A类GPCR配体。生长激素促分泌素受体(GHS-R)是A类GPCR,可通过与其肽配体ghrelin结合来刺激食物摄入。因此,期望GHS-R的拮抗剂发挥抗肥胖作用。在本文中,我们描述了使用cDNA展示技术成功筛选并鉴定GHS-R的拮抗肽。拮抗肽在体外抑制ghrelin诱导的细胞内Ca〜2 +的增加(IC_(50)=约10μM),并抑制对ghrelin的孤立动物胃的收缩。此外,肽的外周给药抑制了小鼠的fooc摄入。这项工作为抗肥胖药的开发提供了新见识,并描述了发现A类GPCR独特肽配体的方法。

著录项

  • 来源
  • 作者单位

    Department of Regulation Biology, Faculty of Science, Saitama University, Sakura-ku, Saitama 338-8570, Japan Department of Functional Materials Science, Faculty of Engineering, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

    Asubio Pharma Co., Ltd., Chuo-ku, Kobe 650-0047, Japan;

    Department of Regulation Biology, Faculty of Science, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

    Department of Regulation Biology, Faculty of Science, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

    Asubio Pharma Co., Ltd., Chuo-ku, Kobe 650-0047, Japan;

    Department of Regulation Biology, Faculty of Science, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

    Asubio Pharma Co., Ltd., Chuo-ku, Kobe 650-0047, Japan;

    Asubio Pharma Co., Ltd., Chuo-ku, Kobe 650-0047, Japan;

    Department of Functional Materials Science, Faculty of Engineering, Saitama University, Sakura-ku, Saitama 338-8570, Japan Janusys Corporation, Saitama Industrial Technology Center, Skip City, Kawaguchi, Saitama 333-0844, Japan;

    Department of Functional Materials Science, Faculty of Engineering, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

    Department of Regulation Biology, Faculty of Science, Saitama University, Sakura-ku, Saitama 338-8570, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    aptamer; in vitro display; peptide drug; ligand screening; cell-based selection;

    机译:适体;体外展示;肽类药物配体筛选基于细胞的选择;
  • 入库时间 2022-08-18 00:40:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号